1. �Ϻ���ͨ��ѧ�����ھ�����ҽԺƤ����
2. �Ϻ���ͨ��ѧҽѧԺ�����ھ�����ҽԺƤ����

�ض������������֢��Ӧ��������������������������Ϊ�ص㣬���ǵ�������Ƶ�һ�����⡣�ض���ķ�����һ������Ⱥ�����ԣ�����������֢�����߷�Ӧ���Ŵ����ء��Լ���ˮƽ������Ӧ����Ӧ��Ѫ����������أ�������ҪΪҩ�����Ƽ��������ƣ����ж���۵�����Ҳ���ض�������к���Ҫ��һ���֡��о��ض���ķ������ƿ���һ���̶���Ԥ�����չΪ�ض��������ָ���ٴ����ơ�

Severe acne is characterized by evident inflammatory reaction, recrudescence and inclination to leave permanent scars. Its treatment is still a troublesome problem over the world. The development of severe acne has a certain tendency in populations, and is related to the inflammatory and immune responses, genetic factors, sexual hormone levels, oxidative stress and serum biochemistry in individuals. Severe acne is mainly managed by medication and physical therapy. The treatment of acne scar is an important part of severe acne management. So, to study the pathogenesis of severe acne may benefit the prevention and control of it.

[1]�й�ҽʦЭ��Ƥ����ҽʦ�ֻ�. �й������ָ��(���۸�). �й�Ƥ������־, 2008, 37(5): 339-342 . [2]Werner Sinclair, H Francois Jordaan. Acne Guideline 2005 Update. SAMJ, 2005, 95(11): 883-892. [3] Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol, 1975, 65:382–384. [4] Toyoda M, Morohashi M. Pathogenesis of acne. Med Electron Microsc, 2001, 34:29–40 [5] Karvonen SL, R?s?nen L, Cunliffe WJ, et al. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans. Dermatology, 1994, 189(4):344-349. [6] Ashbee HR, Muir SR, Cunliffe WJ, et al. IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Br J Dermatol, 1997, 136(5):730-733. [7] Schmidt JB, Pinzker H, Eibl M. Parameters of cellular and humoral immunity in patients with severe acne. Z Hautkr. 1986, 61(19):1397-1404. [8] Abd El All HS, Shoukry NS, El Maged RA, et al. Immunohistochemical expression of interleukin 8 in skin biopsies from patients with inflammatory acne vulgaris. Diagn Pathol, 2007, 2:4. [9] He L, Yang Z, Yu H, et al. The relationship between CYP17 -34T/C polymorphism and acne in Chinese subjects revealed by sequencing. Dermatology, 2006, 212(4):338-342. [10] ������������밮ƽ. Ѱ��������ضȵ�Ӱ�����ط���. [J] �й������Բ�ѧ��־2009��23( 7): 425-428. [11] TAN HH, TAN AWH, BARKHAMT, et a1. Comnmnity—Based sludy of acne vulgaris in adolescents in Singapore. Br J Dermatol, 2007, 157:547—551. [12] Aizawa H, Niimura M. Serum hormone levels in men with severe acne.J Dermatol, 1992, 19(7):404-407. [13] Abdel Fattah NS, Shaheen MA, Ebrahim AA, et al. Tissue and blood superoxide dismutase activities and malondialdehyde levels in different clinical severities of acne vulgaris. Br J Dermatol, 2008, 159(5):1086-1091. [14] Kurutas EB, Arican O, Sasmaz S. Superoxide dismutase and myeloperoxidase activities in polymorphonuclear leukocytes in acne vulgaris. Acta Dermatovenerol Alp Panonica Adriat, 2005, 14(2):39-42. [15] El-Akawi Z, Abdel-Latif N, Abdul-Razzak K. Does the plasma level of vitamins A and E affect acne condition? Clin Exp Dermatol, 2006, 31(3):430-434. [16] Ergin C, Kaleli I, Sahin R, et al. Biotyping of Propionibacterium acnes strains isolated from patients with acne vulgaris. Mikrobiyol Bul, 2006, 40(1-2):15-21. [17] Klaz I, Kochba I, Shohat T, et al. Severe acne vulgaris and tobacco smoking in young men. The Journal of Investigative Dermatology, 2006, 126(8):1749-1752 [18] Hahm BJ, Min SU, Yoon MY, et al. Changes of psychiatric parameters and their relationships by oral isotretinoin in acne patients. J Dermatol, 2009, 36(5):255-261. [19] Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol, 2008, 58(1):60-62. [20] Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg. 2006, 30(6):689-694. [21] Webster G, Rich P, Gold MH, et al. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J Drugs Dermatol, 2009, 8(8):736-743. [22] Abdel-Naser MB, Zouboulis CC. Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris. Expert Opin Pharmacother, 2008, 9(16):2931-2937. [23] Sami NA, Attia AT, Badawi AM. Phototherapy in the treatment of acne vulgaris. J Drugs Dermatol, 2008, 7(7):627-632. [24] Akaraphanth R, Kanjanawanitchkul W, Gritiyarangsan P. Efficacy of ALA-PDT vs blue light in the treatment of acne. Photodermatol Photoimmunol Photomed, 2007, 23(5):186-890. [25] H?rfelt C, Funk J, Frohm-Nilsson M, et al. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol, 2006, 155(3):608-613. [26] Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol, 2006, 54(4):647-651. [27] Deng H, Yuan DF, Yan CL, et al. Fractional 1320 nm Nd : YAG laser in the treatment of acne vulgaris: a pilot study. Photodermatol Photoimmunol Photomed, 2009, 25(5):278-279.